Lower-cost oral weight-loss medications from Novo Nordisk and Eli Lilly are beginning to alter the rapidly expanding obesity treatment market, with doctors reporting that more patients are moving away from compounded alternatives and turning toward branded pharmaceutical products as pricing gaps narrow and access gradually improves.

The shift reflects a broader transition underway in the weight-loss drug industry, where affordability, insurance limitations, safety concerns and brand trust are increasingly influencing prescribing patterns. Physicians interviewed across the United States said the arrival of cheaper oral formulations has started changing patient behavior, particularly among people who had previously relied on compounded versions of obesity drugs because branded injectable treatments were financially out of reach.

The growing interest in oral medications also highlights how the obesity drug market is evolving beyond its initial phase dominated by expensive injections. Drugmakers are now attempting to expand treatment access by introducing more convenient and relatively lower-cost options capable of attracting new groups of patients who were previously hesitant due to cost, needle aversion or insurance barriers.

At the center of this shift are Novo Nordisk’s oral Wegovy and Eli Lilly’s Foundayo, both launched as part of a broader effort to strengthen long-term positions in what has become one of the most competitive and lucrative pharmaceutical sectors globally.

Doctors say many patients who once turned to compounded medications are now reconsidering those choices because the cost advantage of compounded drugs has narrowed significantly. As branded pills move closer in price to compounded alternatives, patients increasingly appear willing to pay for medications backed by large pharmaceutical companies and federal regulatory oversight.

The trend also comes as regulators intensify scrutiny of compounded weight-loss medications following shortages that previously allowed compounding pharmacies to expand rapidly across the market.

Falling Price Gaps Are Changing Patient Decisions

One of the biggest reasons patients are shifting toward branded oral drugs is simple economics.

For much of the recent weight-loss drug boom, branded injectable medications such as Wegovy and Zepbound carried extremely high monthly costs for uninsured or self-paying patients. That pricing structure created an opening for compounded alternatives, which became popular because they offered versions of similar active ingredients at substantially lower prices.

Compounded drugs are legally permitted in certain circumstances, particularly when pharmacies create personalized formulations or when commercial drug shortages exist. During shortages of major GLP-1 obesity treatments, compounded versions expanded rapidly across the United States as demand surged far beyond available supply.

However, doctors now say the introduction of lower-cost oral formulations is beginning to narrow the financial appeal of compounded products.

The lowest-dose versions of oral Wegovy and Foundayo are being priced closer to compounded alternatives than to premium injectable therapies. That has changed the calculation for many patients who previously viewed branded medications as unattainable.

Physicians interviewed about the trend described growing interest from patients specifically asking to move from compounded products to pharmaceutical-grade branded drugs because the price difference no longer appears large enough to justify remaining with compounded options.

This shift reflects broader concerns among both doctors and patients regarding consistency, oversight and quality control in the compounded drug market.

While many compounding pharmacies operate legally and safely, branded medications manufactured by major pharmaceutical firms undergo far more extensive regulatory review, standardized production controls and large-scale clinical testing. As pricing differences shrink, those factors become more influential in patient decision-making.

Doctors say this is especially true among patients seeking long-term obesity treatment rather than temporary weight-loss solutions.

The transition also benefits Novo Nordisk and Eli Lilly strategically because both companies have spent months criticizing widespread use of compounded alternatives. Drugmakers argue that compounded products create safety risks and dilute confidence in GLP-1 therapies overall.

The introduction of cheaper oral products therefore appears partly designed not only to expand access but also to pull consumers back toward regulated branded ecosystems controlled directly by pharmaceutical manufacturers.

Oral Drugs Expand the Market Beyond Injectable Treatments

Another major reason the oral medications are attracting attention is convenience.

Although injectable GLP-1 therapies produced dramatic weight-loss results and transformed the obesity treatment landscape, many patients remained reluctant to begin treatment because of discomfort with injections or concerns about long-term injectable therapy.

The introduction of oral formulations is now opening the market to a broader category of patients who may have previously avoided treatment altogether.

Doctors say some patients who initially declined obesity medications because of cost or injection concerns are now reconsidering treatment due to the newer pill options. In that sense, the oral drugs are not merely competing with compounded products or injectables; they are expanding the overall size of the obesity treatment market itself.

This expansion is strategically important for both Novo Nordisk and Eli Lilly because the long-term commercial opportunity in obesity care depends heavily on reaching much larger patient populations beyond early adopters.

The two companies are also competing aggressively to establish leadership in the oral segment before prescribing habits become firmly established.

Novo appears to benefit currently from stronger brand familiarity because the oral Wegovy pill carries the same name and active drug identity as its highly successful injectable counterpart. Many doctors say patients are already comfortable with the Wegovy brand because it has become one of the most recognizable names in obesity medicine.

The drug’s established cardiovascular data also gives Novo an advantage among some physicians treating patients at elevated heart risk. Clinical evidence showing heart-related benefits beyond weight reduction has strengthened confidence in the broader GLP-1 category and made some doctors more comfortable prescribing Wegovy-based treatments.

Foundayo, meanwhile, represents a somewhat different position in the market.

Although newer and less established in public perception, doctors say it offers practical convenience advantages because it does not require fasting before use. Physicians expect that convenience may become increasingly important over time as patients prioritize treatments that integrate more easily into daily routines.

The competition between the two oral drugs illustrates how the obesity medicine market is evolving beyond simple weight-loss effectiveness toward broader considerations involving lifestyle integration, adherence, accessibility and long-term patient comfort.

Insurance Barriers Continue to Limit Broader Adoption

Despite growing excitement surrounding oral obesity drugs, physicians say insurance coverage remains one of the biggest obstacles preventing wider adoption.

Many patients continue facing repeated denials for GLP-1 therapies, particularly when obesity treatment is categorized as preventive care rather than management of an existing medical condition.

Doctors report that insurance rejections remain common even as obesity increasingly gains recognition as a chronic health issue linked to cardiovascular disease, diabetes and other serious complications.

This insurance challenge explains partly why compounded medications became so popular initially. Many patients unable to secure coverage for branded drugs turned to compounded alternatives because they represented one of the few financially accessible options available.

Although lower-priced oral medications are helping narrow that affordability gap, doctors say costs remain prohibitively high for large segments of the population without meaningful insurance support.

The industry is therefore closely watching the rollout of new Medicare-related coverage programs involving GLP-1 therapies. Physicians hope broader government participation could eventually pressure commercial insurers to expand coverage as well.

If insurance access improves substantially, the obesity drug market could grow dramatically over the next several years.

That potential growth is one reason pharmaceutical companies are racing aggressively to establish strong positions in oral treatments now. The companies appear to recognize that the future obesity market may depend less on a relatively small number of high-paying injectable users and more on attracting millions of long-term patients seeking affordable, scalable and convenient therapies.

Doctors say injectable drugs still dominate among patients already achieving successful results because many are reluctant to switch treatments once weight-loss progress stabilizes. However, the oral drugs appear increasingly effective at attracting new users entering the GLP-1 category for the first time.

This dynamic suggests the obesity treatment market is entering a new phase where growth may increasingly come from accessibility expansion rather than simply escalating demand for premium injectable therapies.

The emergence of lower-cost oral medications is therefore reshaping not only prescribing patterns but also the structure of competition within the broader obesity care industry. Pricing strategy, insurance access, convenience and regulatory trust are becoming just as important as clinical effectiveness as pharmaceutical companies compete for leadership in one of healthcare’s fastest-growing markets.

(Adapted from Investing.com)

Categories: Economy & Finance, Regulations & Legal, Strategy